The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients
-
Published:2022-10-31
Issue:4
Volume:68
Page:1525-1528
-
ISSN:0163-2116
-
Container-title:Digestive Diseases and Sciences
-
language:en
-
Short-container-title:Dig Dis Sci
Author:
Baz M.ORCID, Gondran-Teiller V., Bressac B., Cabaret O., Fievet A., Dimaria M., Goldbarg V., Colas C., Bonnet-Dupeyron M. N., Tinat J., Lebrun M., Mari V., Limacher J. M., Corsini C., Ginglinger E., Saurin J. C., Brahimi A., Rouzier C., Giraud S., Schuster H., Hollebecque A., Boige V., Cauchin E., Malka D., Caron O., Rouleau E.
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,Physiology
Reference17 articles.
1. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012;51:14–24. 2. Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med Off J Am Coll Med Genet. 2015;17:569–577. 3. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360–5364. 4. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381:317–327. 5. Hu Y, Guo M. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. Cancer Sci. 2020;111:3111–3121.
|
|